Table 6 Treatment emergent adverse events, TEAEs (Study 2)
Group | 2A | 2B | 2C |
|---|---|---|---|
N | 8 | 8 | 4 |
Patients with any TEAE | 8 (100%) | 5 (63%) | 1 (25%) |
Patients with any serious AE | 4 (50%) | 2 (25%) | 0 |
Patients with TEAE leading to treatment discontinuation | 2 (25%) | 2 (25%) | 0 |
Malaria | 7 (88%) | 4 (50%) | 0 |
Hepatitis B | 1 (13%) | ||
Neutropenia | 0 | 2 (25%) | 0 |
Decreased appetite | 0 | 1 (13%) | 0 |
Headache | 0 | 0 | 1 (25%) |
Lacrimation increased | 1 (13%) | 0 | 0 |
Vision blurred | 1 (13%) | 0 | 0 |
Vertigo | 1 (12.5%) | 0 | o |
Gastrointestinal disorders | 4 (50%) | 1 (13%) | 0 |
Jaundice | 1 (13%) | 0 | 0 |
Pyrexia | 0 | 0 | 1 (25%) |